Objective: To measure the association between oral contraceptive use and the prevalence of genital warts in women. Methods: Cross sectional case control study comparing oral contraceptive use in women with and without genital warts attending a city centre genitourinary medicine clinic controlling for recent sexual activity, the presence of other sexually transmitted infections, socio-economic class and history of pregnancy using a multivariate logistic regression model. Results: After controlling for potential confounding variables women with genital warts were significantly more likely to be current users of the oral contraceptive pill (OR 1.7, 95% CI 1.3-2-2). Conclusion: The study suggests that women taking the oral contraceptive may be at increased risk of presenting with genital warts. Previously published papers provide some support for this hypothesis and potential biological mechanisms are discussed.
Introduction
Genital warts are one of the commonest conditions diagnosed and treated in genitourinary medicine clinics and the prevalence of human papillomavirus (HPV) infection continues to increase in contrast to the decline in many bacterial sexually transmitted infections in the UK.' The association between certain subtypes of HPV history of pregnancy, the number of sexual partners within the past 3 months, the socio-economic class of the patient (based on occupation) and whether the patient was currently taking oral contraceptives. This information was routinely recorded on a proforma within the notes of each patient at the first visit.
An initial power analysis showed that 842 patients would be required to have an 80% chance of detecting a 1.5 fold difference in the use of oral contraceptive between patients with and without warts, with 95% confidence. A multivariate logistic regression model was used to compare the use of oral contraceptives in patients with and without genital warts controlling for sexual activity, age, presence of LZ Patients with Warts (n = 429) ME Control Group (n = 418) over prolonged periods, this failed to reach statistical significance. However, the presence of clinically apparent warts was significantly associated with long-term (over 5 years) OCP use in a case control study from Washington. '8 There has also been an anecdotal report of recalcitrant genital warts which regressed after the withdrawal of oral contraceptives.'9 The role of the OCP in genital cancers is controversial but may be protective for ovarian and endometrial tumours202' but increase the risk of cervical dysplasia (particularly high grade changes) and possibly cancer.22 26 Therefore despite the cross sectional design of our study, which presents difficulties in establishing a cause and effect relationship, there is a biological basis for oral contraceptives increasing the prevalence of clinically apparent genital warts (via depressed cellular immunity) and a possible dose response effect with some studies suggesting that prolonged exposure is required before an effect is apparent.
It was not possible to control for all potential confounding factors owing to the retrospective study design. Although the length of time that each patient had been sexually active was not known the patient's age may have provided an indirect assessment of this. Age at first intercourse and lifetime number of partners could also not be compared in the study and control groups. The oestrogen dose in different preparations of OCP may be relevant to the risk of genital warts, as may the total length of time on the OCP and neither of these could be assessed accurately from the present study design. Another potential confounder is condom use since those using the OCP are less likely to use barrier protection and any effect seen may reflect the lack of a condom rather than the use of the OCP. Unfortunately this information was not reliably collected in the casenotes.
In restricting the analysis to genitourinary medicine clinic attenders there is also a potential recruitment bias in those studied. Thus it is possible that clinic attenders with genital warts may differ from other patients in the community with warts who do not attend a GU clinic for treatment. There is increasing evidence, however, that sexual behaviour patterns and STD rates differ little between patients attending genitourinary clinics, family planning clinics and in general practice.27 29 Patients with genital warts were twice as likely not to admit to having had a sexual partner within the preceding 3 months. This may have been the result of embarrassment associated with having visible signs of a sexually transmitted infection inhibiting the formation of new relationships. The present study also suggests that once warts present clinically patients are no more, and possibly less, sexually active than those attending the clinic without warts, even before being provided with health education and advice. The low prevalence of concurrent STDs in patients with warts compared to genitourinary medicine clinic attenders without warts also suggests that this group may be less sexually active or using additional barrier methods of contraception.
The relatively few studies that have assessed the association between genital warts and oral contraceptive use have generally done so in a family planning or colposcopy setting and although there is limited evidence for the asymptomatic detection of HPV being associated with taking the OCP, the evidence from this and other studies supports a limited role for oral contraceptives in the prevalence of clinical condylomata acuminatum. The major problem in interpreting these studies is the large number of other factors which may influence the prevalence of genital warts and which may act as confounders for OCP use. Thus a prospective trial using the published studies as a basis for the trial design and permitting the inclusion of these confounding factors is required to strengthen the hypothetical link between oral contraceptives and genital warts.
